8-K: Adagio Medical Secures $19M in Private Placement

Adagio Medical Holdings, Inc. announced a private placement raising $19 million upfront, with potential for an additional $31 million from warrant exercises, to fund clinical and product development.

Summary

• Adagio Medical Holdings, Inc. entered into a Securities Purchase Agreement on October 14, 2025, for a private placement with certain accredited investors.
• The company will issue 9,792,506 shares of common stock (or pre-funded warrants) and accompanying Tranche A, B, and C Milestone Warrants.
• The private placement is expected to generate approximately $19 million in upfront gross proceeds.
• An additional approximately $31 million in gross proceeds may be received if the Milestone Warrants are fully exercised for cash.
• The combined purchase price for each share and accompanying Milestone Warrants is $1.9403.
• The combined purchase price for each pre-funded warrant and accompanying Milestone Warrants is $1.9402.
• Entities affiliated with Perceptive Advisors LLC, an existing affiliate, participated by purchasing shares and Milestone Warrants for an aggregate of $4,250,000.
• Proceeds are intended for working capital and general corporate purposes, including advancing clinical and product development activities.

Sentiment

Score: 7

Explanation: The successful private placement provides Adagio Medical with significant upfront capital and a clear path to additional funding tied to key product development and regulatory milestones. The participation of an existing affiliate investor signals continued confidence. While dilution is a factor, the capital infusion is crucial for advancing its innovative cryoablation technologies.

Positives

• Secured $19 million in upfront gross proceeds, providing immediate capital for operations.
• Potential for an additional $31 million in gross proceeds from warrant exercises, offering future funding flexibility tied to key milestones.
• Participation from an affiliate of existing investor Perceptive Advisors LLC, indicating continued investor confidence.
• Funds are earmarked for working capital and advancing clinical and product development, supporting core business growth and innovation.
• The structure with Milestone Warrants ties potential future funding to key clinical and regulatory achievements, including FULCRUM-VT IDE trial results and FDA approvals for vCLAS Cryoablation System and second-generation vCLAS catheter system.

Negatives

• The issuance of new shares and warrants could lead to significant dilution for existing shareholders upon exercise.
• Cash penalties will apply to the Company in the event of registration failures for the resale of the securities, potentially impacting financial performance.
• The company is identified as an 'emerging growth company,' which may imply higher inherent risks or less established operations compared to larger, more mature firms.

Risks

• The securities have not been registered under the Securities Act of 1933 or state securities laws and may not be sold, transferred, or assigned without registration or an applicable exemption (e.g., Rule 144).
• The exercise of warrants is subject to beneficial ownership limitations (initially 4.99% or 9.99%, adjustable up to 19.99%), which could restrict a holder's ability to fully exercise immediately.
• The company faces various risks described in its SEC filings, including its Annual Report on Form 10-K for the full-year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from expectations.
• The company's ability to meet its obligations under the Registration Rights Agreement (e.g., filing and effectiveness deadlines) could result in liquidated damages.
• The SEC may take the position that the offering of some or all Registrable Securities is a primary offering or not eligible for delayed/continuous basis under Rule 415, potentially requiring cut-backs or naming investors as underwriters.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the advancement of its clinical and product development activities. Key future milestones tied to warrant expiration include the announcement of results from the FULCRUM-VT IDE pivotal clinical trial, U.S. FDA approval of the vCLAS Cryoablation System, and U.S. FDA approval of the second-generation vCLAS catheter system.

Management Comments

• Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology.
• ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue.
• The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. IDE Pivotal Study.

Industry Context

This private placement provides Adagio Medical with capital to continue its development in the competitive medical device sector, specifically in catheter ablation technologies for cardiac arrhythmias. The focus on Ultra-Low Temperature Cryoablation (ULTC) technology positions the company in an innovative segment, aiming to differentiate its solutions for conditions like ventricular tachycardia. The milestones tied to FDA approvals and clinical trial results are typical for medical device companies seeking to bring new technologies to market, indicating a standard progression within the industry.

Comparison to Industry Standards

• The company's vCLAS Cryoablation System is CE Marked, indicating compliance with European health, safety, and environmental protection standards, which is a common benchmark for medical devices seeking international market access.
• The FULCRUM-VT U.S. IDE Pivotal Study is a critical step for FDA approval, aligning with standard regulatory pathways for novel medical devices in the United States, comparable to studies undertaken by companies like Medtronic or Boston Scientific for their cardiac ablation systems.
• The pursuit of FDA approvals for both the vCLAS Cryoablation System and a second-generation vCLAS catheter system demonstrates a commitment to product pipeline development, a strategy seen across leading medical technology firms to maintain competitive advantage and expand market share.

Related Party Transactions

• Entities affiliated with Perceptive Advisors LLC, an affiliate of the Company, purchased Shares and Milestone Warrants for an aggregate purchase price of $4,250,000.

Stakeholder Impact

• Shareholders: Potential for dilution from the issuance of new shares and warrants. However, the capital raise supports the company's long-term growth and product development, which could benefit shareholders if successful.
• Investors (Purchasers in Private Placement): Gain equity and warrants with potential upside, but face beneficial ownership limitations and reliance on future milestones for full warrant value.
• Employees: Continued funding supports ongoing clinical and product development, potentially ensuring job security and progress on key projects.
• Customers/Patients: The funding is directed towards advancing clinical trials and product development for cardiac arrhythmia treatments, potentially leading to new or improved medical solutions.

Next Steps

• File a registration statement with the SEC covering the resale of the Shares and Warrant Shares no later than the 45th day following October 14, 2025.
• Use reasonable best efforts to have the registration statement declared effective within a specified period after the filing deadline.
• Announce results from the FULCRUM-VT IDE pivotal clinical trial (triggers Tranche A Warrant expiration).
• Seek U.S. FDA approval for the vCLAS Cryoablation System (triggers Tranche B Warrant expiration).
• Seek U.S. FDA approval for the second-generation vCLAS catheter system (triggers Tranche C Warrant expiration).
• Close the private placement during the week of October 13, 2025, subject to customary closing conditions.

Key Dates

Recommendation

The private placement provides essential capital for Adagio Medical's clinical and product development, which is a positive for an emerging growth company in the medical device space. The participation of an existing affiliate investor like Perceptive Advisors suggests continued confidence. However, the significant potential for dilution from the warrants, coupled with the inherent risks of clinical trials and regulatory approvals in the medical device industry, warrants a cautious 'hold' recommendation. Investors should monitor the progress of the FULCRUM-VT IDE trial and FDA approvals, as these milestones are critical for future value creation and warrant exercise.

Keywords

Adagio Medical Holdings, ADGM, Private Placement, Securities Purchase Agreement, Warrants, Pre-Funded Warrants, Milestone Warrants, Capital Raise, Cryoablation, Cardiac Arrhythmias, FULCRUM-VT IDE, FDA Approval, Medical Device, Perceptive Advisors, Equity Financing